Blog

Revolutionizing Glaucoma Treatment with Adaptive Trials and Patient Focus Glaucoma, a leading cause of irreversible blindness worldwide, has long been a challenge for both patients and healthcare providers. Traditional treatment approaches often follow a one-size-fits-all model, which may not account for individual patient variability. However, the future of glaucoma management is evolving with adaptive clinical

# MINIject® Shows 5-Year Efficacy in Glaucoma Treatment in STAR-GLOBAL Trial ## Introduction Glaucoma, a leading cause of irreversible blindness worldwide, has long posed challenges for both patients and ophthalmologists. Traditional treatments, including eye drops and surgical interventions, often come with limitations such as poor patient compliance or invasive procedures. However, a breakthrough in glaucoma

# Perfuse Therapeutics to Present PER-001 Glaucoma Implant at ARVO Meeting ## Introduction Perfuse Therapeutics, a pioneering biotech company specializing in innovative ophthalmic treatments, is set to unveil its groundbreaking PER-001 glaucoma implant at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. This highly anticipated presentation marks a significant milestone in

# How Fovea-Disc Distance Affects Glaucoma Scan Accuracy Glaucoma is a leading cause of irreversible blindness worldwide, and early detection is crucial for preventing vision loss. One of the key diagnostic tools for glaucoma is **optical coherence tomography (OCT)**, which measures the thickness of the retinal nerve fiber layer (RNFL). However, the accuracy of these

# Sanoculis’ MINT® Glaucoma Treatment Secures CE Mark Approval ## A Breakthrough in Glaucoma Management The medical technology sector has witnessed a significant milestone with **Sanoculis** receiving **CE Mark approval** for its innovative **MINT® Glaucoma Treatment**. This cutting-edge solution promises to revolutionize how glaucoma is managed, offering a minimally invasive approach to reducing intraocular pressure

Breakthrough Glaucoma Treatments Offer New Hope for Patients Glaucoma, often called the “silent thief of sight,” is a leading cause of irreversible blindness worldwide. For years, treatment options were limited to eye drops, laser therapy, and invasive surgeries. However, recent advancements in medical science are revolutionizing how we manage this condition. Today, breakthrough glaucoma treatments

Open Angle Glaucoma Clinical Trials 2025: FDA, EMA, and NICE Approvals Open-angle glaucoma (OAG) remains one of the leading causes of irreversible blindness worldwide. With an aging population and increasing prevalence, the demand for innovative treatments is higher than ever. The year 2025 is poised to be a landmark period for OAG clinical trials, with

Innovative Minimally Invasive Glaucoma Treatments in Development Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of people. Traditional treatments, such as eye drops and invasive surgeries, have limitations, including side effects and variable efficacy. However, recent advancements in medical technology are paving the way for minimally invasive glaucoma treatments (MIGS) that promise